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Abstract
Background: Endometrial cancer is the most common gynaecological malignancy; risk factors include exposure to oestrogens
and high body mass index. Expression of enzymes involved in biosynthesis of oestrogens and prostaglandins (PG) is often higher
in endometrial cancers when compared with levels detected in normal endometrium. Oestrogens bind one of two receptors
(ERα and ERβ) encoded by separate genes. The full-length receptors function as ligand-activated transcription factors; splice
variant isoforms of ERβ lacking a ligand-binding domain have also been described. PGs act in an autocrine or paracrine manner
by binding to specific G-protein coupled receptors.
Methods: We compared expression of ERs, progesterone receptor (PR) and cyclooxygenase-2 (COX-2) in stage 1 endometrial
adenocarcinomas graded as well (G1), moderately (G2) or poorly (G3) differentiated (n ≥ 10 each group) using qRTPCR, single
and double immunohistochemistry. We used endometrial adenocarcinoma cell lines to investigate the impact of PGF2α on
expression of ERs and PR.
Results: Full length ERβ (ERβ1) and two ERβ variants (ERβ2, ERβ5) were expressed in endometrial cancers regardless of grade
and the proteins were immunolocalised to the nuclei of cells in both epithelial and stromal compartments. Immunoexpression
of COX-2 was most intense in cells that were ERαneg/low. Expression of PR in endometrial adenocarcinoma (Ishikawa) cell lines
and tissues broadly paralleled that of ERα. Treatment of adenocarcinoma cells with PGF2α reduced expression of ERα but had
no impact on ERβ1. Cells incubated with PGF2α were unable to increase expression of PR mRNA when they were incubated
with E2.
Conclusion: We have demonstrated that ERβ5 protein is expressed in stage 1 endometrial adenocarcinomas. Expression of
three ERβ variants, including the full-length protein is not grade-dependent and most cells in poorly differentiated cancers are
ERβpos/ERαneg. We found evidence of a link between COX-2, its product PGF2α, and expression of ERα and PR that sheds new
light on the cross talk between steroid and PG signalling pathways in this disease.
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Background
Endometrial cancer is the most common gynaecological
malignancy and accounts for 5% of cancers in women
http://info.cancerresearchuk.org/cancerstats/. The major-
ity of endometrial cancers occur in post-menopausal
women and 80% of patients are diagnosed when the
tumour is confined to the uterus (stage 1 disease). Many
of the established risk factors for developing endometrial
cancer are associated with excess exposure to oestrogen
unopposed by progesterone. For example, several studies
have reported that use of oestrogen-only hormone
replacement therapy (HRT) increases the risk of develop-
ing both localized and widespread endometrial cancer
[1,2]. The menopausal transition (perimenopause), a
time when oestrogens may be elevated and anovulatory
cycles mean that progesterone levels are reduced, has been
proposed as a possible 'window of risk' for the develop-
ment of the disease [3]. A high body mass index (BMI)
[4,5] increases the risk of developing endometrial cancer
and patients with a high BMI have a poorer prognosis [6].
Expression of enzymes involved in biosynthesis of oestro-
gens such as CYP19A1 and 17β HSD type 2 have been
documented in endometrial carcinomas [7,8] and con-
centrations of oestradiol (E2) in tumour tissues have been
correlated positively with the clinical stage of disease and
rate of tumour invasion in both pre- and post-menopau-
sal women [9].
The impact of oestrogenic ligands on endometrial cells is
mediated via oestrogen receptors that act as ligand-acti-
vated transcription factors. There are two oestrogen recep-
tors, ERα [ESR1] and ERβ [ESR2], encoded by different
genes. The human ERβ gene is alternatively spliced at its 3'
end resulting in formation of mRNAs that encode not
only a full-length protein (ERβ1) capable of binding to E2
but also truncated isoforms (ERβ2, ERβ5) lacking an
intact binding pocket [10]. Expression of ERs in normal
pre-menopausal endometrium has been well docu-
mented with immunoexpression of ERα being intense in
both glands and stroma during the proliferative, oestro-
gen-dominant phase but reduced in the secretory phase
following the post ovulatory rise in progesterone [11].
ERβ1 and ERβ2 are both expressed during the proliferative
phase however following ovulation ERβ1 continues to be
expressed, ERβ2 is selectively down-regulated in the glan-
dular epithelium [12] and the pattern of expression of
ERβ5 has not been described.
In normal endometrium expression of progesterone
receptor (PR) is induced during the oestrogen-dominated
proliferative phase and a number of response elements
capable of activation by ERs have been described within
the regulatory region of the PR gene [13]. During the
secretory phase when circulating concentrations of pro-
gesterone are maximal activation of PR results in reduced
proliferation and increased cellular differentiation. If pro-
gesterone biosynthesis is inadequate/absent as might
occur during anovulatory cycles the endometrium can
become hyperplastic. Notably, development of complex
atypical hyperplasia carries a 25% risk of developing sub-
sequent endometrial adenocarcinoma. Biochemical stud-
ies record lower concentrations of ER and PR in
endometrial cancers from clinical stages III-IV than those
from clinical stage I; in stage I samples higher concentra-
tions of receptor were measured in the well and moder-
ately differentiated samples [14]. In endometrial
carcinomas mRNAs for several ERβ isoforms have been
detected [15-17] but detailed immunolocalisation studies
comparing their expression have not been reported. It has
been claimed that PR immunohistochemistry provides
the most reliable means for predicting survival in
endometrial adenocarcinoma [18], that detection of PR is
associated with better disease free survival [19] and that
administration of progestins is an effective treatment for
pre-menopausal women with endometrial carcinomas or
atypical hyperplasia [19].
In the reproductive tract, the predominant prostaglandins
are the E- and F-series prostanoids [20]. These are synthe-
sised from arachidonic acid by cyclooxygenase (COX) and
prostaglandin synthase enzymes and act in an autocrine
or paracrine manner by binding to specific G-protein cou-
pled receptors (GPCR; reviewed in [21]). There is emerg-
ing evidence supporting a complex interplay between the
production and action of oestrogens and prostaglandins
within the microenvironment of tumours and endome-
trial pathologies such as endometriosis. For example, E2
can increase expression of COX enzymes [22,23] and the
existence of an oestrogen response element has been doc-
umented in the promoter of the gene encoding prostag-
landin synthase enzymes [24]. There is convincing
evidence that PGE2 stimulates biosynthesis of oestrogens
by enhancing expression of the aromatase (CYP19A1)
gene in endometriotic tissue [25] and expression of aro-
matase can be suppressed by COX-2 selective inhibitors
[26].
In endometrial adenocarcinoma, expression of COX-2 but
not COX-1 is upregulated compared with normal
endometrium [27,28]. Moreover, we have demonstrated a
role for the F Prostanoid (FP) receptor (the receptor for
prostaglandin PGF2α) in endometrial adenocarcinoma,
with evidence that elevated PGF2α-FP receptor signalling
results in an up regulation in expression of angiogenic and
tumorigenic genes including COX-2 [29], FGF2 [30] and
VEGF [31] as well as an increase in proliferation and
migration of neoplastic epithelial cells [32]. In the present
study we investigated whether expression of ERs, includ-
ing ERβ variants, could be correlated with the degree of
differentiation of grade 1 tumours and/or expression ofBMC Cancer 2009, 9:330 http://www.biomedcentral.com/1471-2407/9/330
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PR and COX-2. We also investigated the impact of PGF2α
on expression of ERα, ERβ and PR in cancer-derived
endometrial epithelial cells.
Methods
Patients and tissue collection
Endometrial adenocarcinoma tissue was collected from
post-menopausal women undergoing total abdominal
hysterectomy who had been previously diagnosed to have
endometrioid adenocarcinoma of the endometrium; they
had received no treatment before surgery. Written
informed consent was obtained from all patients; ethical
approval was obtained from the Lothian Research Ethics
Committee. All endometrial cancers were confined to the
uterus (International Federation of Obstetrics and Gynae-
cology, FIGO, stage 1 [33]). Diagnosis of adenocarcinoma
was confirmed histologically and tissues were further
graded as well differentiated (G1), moderately differenti-
ated (G2) or poorly differentiated (G3) by an experienced
gynaecological pathologist. A minimum of 10 samples at
each grade was analysed, tissue for immunohistochemis-
try was collected in neutral buffered formalin (NBF) RNA
extraction samples were collected in RNALater (Qiagen,
UK).
Cell cultures
Two endometrial adenocarinoma cell lines derived from
different patients were used. The first cell line [Ishikawa A]
was obtained from the European Collection of Cell Cul-
ture (ECACC no 99040201, Wiltshire, UK) and main-
tained in DMEM (Sigma, Poole, UK). This cell line was
originally derived from a well-differentiated adenocarci-
noma of a 39 year-old woman and characterised as con-
taining ER and PR [34]. A second cell line [Ishikawa B],
previously characterised as ERα-negative [35], was derived
from the tumour of an unrelated patient with the same
last name. Cells were maintained in DMEM (Sigma) sup-
plemented with 10% FBS, 100 U penicillin, streptomycin
and 0.25 ug/ml fungizone (Invitrogen, Paisley, UK) at
37°C in 5% CO2. An additional cell line derived from the
Ishikawa A cells following stable transfection with FP
receptor cDNA [ERαpos/FPpos] was maintained with the
addition of 200 μg/ml G418 [31]. Cells were treated with
oestradiol 17β (E2) using stocks diluted in DMSO to give
final concentrations in the range 10-7 to 10-10 M or pros-
taglandin F2α at a final concentration of 100 nm [stock
solution prepared in ethanol]; appropriate vehicle control
incubations were included in all studies.
RNA extraction and Taqman quantitative RT-PCR
Total RNA was extracted using the RNAeasy mini kit (Qia-
gen, Sussex, UK) with additional purification by centrifu-
gation through QIAshredder spin columns (Qiagen). RNA
concentration and purity was calculated using the Nano-
drop (LabTech International, Lewes, Sussex, UK) and
standardised to 100 ng/μl for all samples. The reverse
transcriptase reaction consisted of 400 ng of RNA, 2.5 μM
random hexamers in 1× PCR buffer II, 5 mM MgCl2, 1 mM
dNTP's, 1 U/μl RNase inhibitor and 2.5 U/μl Multiscribe
RT (Applied Biosystems, Foster City, USA) incubated at
25°C for 20 minutes, 42°C for 60 minutes followed by 5
minutes at 95°C. A pooled RNA control supplied by ABI
was included as a reference sample in all reactions. Quan-
titative PCR was performed using FAM labelled probes
from the Universal Probe Library (Roche Diagnostics, Bur-
gess Hill, UK) and specific primers for the ERα, ERβ1, 2, 5
and PR (Table 1). Each 20 μl reaction consisted of 2 μl of
cDNA in 1× Faststart master mix (Roche) with additional
Rox dye to a final concentration of 510 nM with 200 nM
of forward and reverse primer, 50 nM probe, 0.02 μM of
18S primers and 0.08 uM 18S probe; 40 cycles of PCR
[95°C for 15 s followed by 60°C for 1 minutes] were car-
ried out using the ABI Prism 7900HT sequence detection
system (Applied Biosystems, Foster City, USA).
Luciferase ERE reporter assays
An adenoviral vector containing a 3xERE-tk-luciferase
reporter gene was prepared according to a standard proto-
col (Microbix) from a plasmid that was a kind gift from
Professor DP McDonnell ([36], Duke University NC,
USA). A full-length human ERα cDNA (see [37]) was used
to prepare viral constructs using an identical strategy. The
resulting viral particles were plaque purified, amplified in
Hek293 cells and concentrated using a commercial kit
(Vivascience). Cells [1 × 105] were plated in 24 well tissue
culture plates in DMEM containing charcoal stripped foe-
tal calf serum (CSFCS) and cultured for 24 hours before
being infected with Ad-ERE-Luc at a MOI of 100. After a
further 24 hours cells were incubated with E2 [10-7 to 10-
Table 1: Details of primers and probes used for quantitative PCR
cDNA Forward Primer Reverse Primer Roche Probe
ERα ttactgaccaacctggcaga atcatggagggtcaaatcca 24
ERβ1 gctcctgtcccacgtcag tgggcattcagcatctcc 62
ERβ2 tgggtgattgccaagagc gtttgagaggccttttctgc 52
ERβ5 gctcctgtcccacgtcag cacataatcccatcccaagc 17
PR tttaagagggcaatggaagg cggattttatcaacgatgcag 11BMC Cancer 2009, 9:330 http://www.biomedcentral.com/1471-2407/9/330
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10 M] for 24 hours and luciferase activities were deter-
mined using 'Bright Glo' reagents (Promega,).
Immunohistochemistry
Single antibody immunohistochemistry (IHC)
Details of primary antibodies are given in Table 2. The
specificity of the antibodies directed against the ERβ vari-
ants has already been validated using Western blotting
[38,39]. Slide-mounted 5 μm sections were subjected to
heat-induced antigen retrieval according to standard
methods [40] (Table 2). Sections were incubated with 3%
(v/v) hydrogen peroxide in methanol for 30 minutes to
block endogenous peroxidase, washed and transferred
into Tris-buffered saline (TBS; 0.05 M Tris [pH 7.4],
0.85% saline) for 5 minutes. Non-specific binding was
blocked using normal rabbit serum (NRS, Biosera)
diluted 1:4 in TBS containing 5% BSA (NRS/TBS/BSA)
[ERα, ERβ2] or normal goat serum (NGS, Biosera) diluted
1:4 in TBS containing 5% BSA (NGS/TBS/BSA) [ERβ1,
ERβ5]. An avidin biotin block was performed using rea-
gents from Vector (Blocking kit, Cat. No. SP-2002, Peter-
borough, UK). Primary antibodies were diluted in the
appropriate blocking serum (Table 2) and incubated on
sections overnight at 4°C. Sections were washed twice and
incubated with the appropriate biotinylated secondary
antibodies diluted at 1:500 (30 min), washed again and
incubated in Streptavidin-HRP (DAKO; P0397) for 30
minutes, before bound antibodies were visualized by
incubation with 3,3'-diaminobenzidine tetra-hydrochlo-
ride (liquid DAB+, product no. K346811, Dako).
Double fluorescent immunohistochemistry
An overview of the protocol used for each of the combina-
tions of antibodies used for double fluorescent immuno-
histochemistry is summarised in Table 3. Note the
antibody directed against PR will cross-react with both A
and B forms of the protein. In all cases initial antigen
retrieval was carried out in citrate buffer [40], biotin con-
jugates were diluted in NGS/PBS/BSA, fluorescent conju-
gates were diluted in PBS, primary antibodies were diluted
in NGS/PBS/BSA and incubated overnight at 4°C. All
washes carried out between antibody incubations were in
PBS and were repeated twice for 5 minutes each. Details of
secondary antibodies and stains are given in Table 4.
Statistical analysis
Statistical differences were determined by ANOVA fol-
lowed by post hoc Bonferroni multiple comparison test.
Values are expressed as mean +/- SD and P < 0.05 was con-
sidered statistically significant.
Results
Expression of oestrogen receptors in stage 1 endometrial 
cancers
The amount of ERα mRNA was significantly lower in
poorly differentiated cancers compared with cancers
graded as well or moderately differentiated (Figure 1A).
Messenger RNAs for ERβ1 (Figure 1B), ERβ2 (Figure 1C)
and ERβ5 (Figure 1D) did not vary significantly with
grade although there was a trend for a reduction in the
total amount of ERβ1 mRNA in the poorly differentiated
cancers.
Expression of ERβ isoforms (ERβ1,  β2 and β5) was
detected using variant-specific monoclonal antibodies, All
three proteins were immunolocalised to cell nuclei and in
the well and moderately differentiated tissues positive
staining was detected in both epithelial and stromal com-
partments (Figure 2B, C, D, F, G, H). Immunoexpression
of ERβ5 was intense in most samples regardless of grade
(Figure 2D, H, M). Consistent with previous reports
immunoexpression of ERα was intense in epithelial cell
nuclei in well and moderately differentiated cancers (Fig-
ure 2A, C arrowheads in panel A and at higher power in
the inset of panel E) but little or no protein was detected
in the poorly differentiated cancers (Figure 2J). The inset
in Figure 2 panel J illustrates some of the few immunopo-
sitive cells detected in the poorly differentiated samples all
of which appeared to have a stromal/fibroblast pheno-
type.
Table 2: Details of primary antibodies
Target Clone Supplier DAB concentration Antigen retrieval
ERα mouse 6F-11 Novocastra 1:120 0.01 M Citrate buffer (pH6) for 5 minutes
ERβ1 mouse PPG5/10 Serotec, [60] 1:40 0.05 M Glycine/EDTA (pH8) for 5 minutes
ERβ2 mouse 57/3 Serotec, [38] 1:30 0.05 M Glycine/EDTA (pH8) for 5 minutes
ERβ5 mouse 5/25 Serotec, [61] 1:75 0.01 M Citrate buffer (pH6) for 5 minutes
PR (A+B) rabbit C19 Santa Cruz N/A 0.01 M Citrate
(pH6) 10 min
COX-2 goat C20 Santa Cruz N/A 0.01 M Citrate
(pH6) 10 min
**Details of secondary antibodies are given in Table 4.BMC Cancer 2009, 9:330 http://www.biomedcentral.com/1471-2407/9/330
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Expression of PR was down regulated in the poorly 
differentiated cancers and paralleled expression of ERα
The amount of PR mRNA in endometrial cancer homoge-
nates was grade dependent and was significantly lower in
the poorly differentiated cancers compared to those clas-
sified as well or moderately differentiated (Figure 3A).
Incubation of ERα-positive Ishikawa (A) cells with 10-8M
E2 resulted in a significant, time dependent, increase in
expression of PR mRNA reaching ~25 fold above controls
at 24 h however there was no detectable increase in
expression of PR mRNA in ERα-negative Ishikawa cells
(Figure 3B). Both Ishikawa cell lines expressed mRNAs for
ERβ1, ERβ2 and ERβ5 with higher concentrations in the
ERα-negative cells [see Additional file 1]. The presence of
functional ERs was confirmed using a luciferase reporter
transgene driven by a 3xERE response element [see Addi-
tional file 1]; as expected in ERα-positive cells expression
of luciferase was induced by E2; no increase in reporter
gene activity was detected in the ERα-negative cells unless
the cells were infected with an adenoviral construct con-
taining an ERα cDNA. These results demonstrate that
although the cells contain all the factors essential for
induction of ERE-dependent gene expression this could
not be induced by ligand-activation of ERβ1.
Fluorescent immunohistochemistry revealed that PR was
widely expressed in the nuclei of epithelial cells in both
well and moderately differentiated cancers but most cells
in the poorly differentiated samples were immunonega-
tive (Figure 3C). Most, but not all, of the epithelial cells
within the well and moderately differentiated cancers co-
expressed both PR and ERα (yellow/orange nuclei, Figure
3C). In the poorly differentiated cancers very few cells
were immunopositive for PR and most of these were ERα-
positive with a fibroblastic phenotype (Figure 3C, labelled
** in upper right panel). Co-immunostaining for PR and
ERβ1 identified cells that were ERβ1 positive/PR negative
in the epithelial layer of the well differentiated cancers
(e.g. arrowheads lower left panel). In the poorly differen-
tiated cancers the majority of cells that were immunopos-
itive for ERβ1 did not express PR (green nuclei) although
the population of fibroblastic cells identified in the same
samples stained with ERα (see above) were PR positive
and a few co-expressed ERβ1 (yellow nuclei, ** Figure 3C
lower right).
Expression of COX-2 in epithelial cells is associated with 
reduced expression of ERα
Immunoexpression of COX-2 was localised specifically to
the cytoplasm of epithelial cells in the well (n = 10) and
moderately (n = 9) differentiated cancers (Figure 4 red
staining). In well and moderately differentiated samples
the amount of ERα in cell nuclei generally appeared to be
lower in the COX-2 positive cells (arrows) than in the sur-
rounding tissue (intense green staining of ERα-positive
cell nuclei) and in the poorly differentiated samples
nearly all the COX-2 positive cells were ERα-negative
prompting us to use a model cell line to explore whether
treatment of cells with prostaglandin F could have an
impact on expression of ERα. PGF2α was used in these
studies as our previous work had shown that this prostag-
landin is synthesised in endometrial adenocarcinomas
[41] and can drive epithelial cell proliferation in endome-
trial tissue [32].
Incubation of Ishikawa cells with prostaglandins alters 
expression of ERα and PR
Incubation of Ishikawa cells expressing both ERα and the
FP receptor [31] with PGF2α resulted in a significant (p <
Table 3: Details of protocols used for fluorescent co-localisation.
ERβ1+PR ERα +PR COX2+ ERα
Citrate retrieve Citrate retrieve Citrate retrieve
Methanol/peroxide block NGS block NRS block
NGS block Avidin block Avidin block
Avidin block Biotin block Biotin block
Biotin block ERα 1:20 COX-2 1:60
PR 1:50 GAM 488 RAGB
GARB NGS block Streptavidin 546
Streptavidin 546 PR 1:50 NGS
NGS block GARB ERα 1:20
ERβ1 1:200 Streptavidin 546 GAM 488
GAMP To-Pro To-Pro
Tyramide fluoresein
To-Pro
The protocol for each combination of stains is given in the vertical 
columns; all sections are pre-blocked with normal goat serum
Table 4: Secondary antibodies and counterstains
Antibody Abbreviation Supplier Product no. Dilution
Goat anti rabbit biotinylated GARB Dako E0432 1:500
Goat anti mouse biotinylated GAMB Dako E0433 1:500
Goat anti-mouse Alexa Fluor 488 GAM 488 Mol. Probes A-11029 1:200
Avidin Alexa Fluor 488 Avidin 488 Mol. Probes A-21370 1:200
Streptavidin Alexa Fluor 546 Streptavidin 546 Mol. Probes S-11225 1:200
Tyramide fluorescein Tyramide fluorescein Perkin Elmer Life Sciences NEL 744 1:50
To Pro To Pro Mol. Probes T3605 1:1000BMC Cancer 2009, 9:330 http://www.biomedcentral.com/1471-2407/9/330
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0.005) and sustained down-regulation in expression of
ERα mRNA (Figure 5A) but no significant change in the
amount of ERβ1 mRNA (Figure 5B). In a follow up study
the ability of cells to up-regulate expression of PR mRNA
in response to treatment with E2 (10-8M, 24 hours) was
investigated in control cells and those pre-incubated with
ERα for 24 hours. In line with expectations incubation of
control cells with E2 for 24 hours resulted in increased
expression of PR mRNA however pre-incubation with
PGF2α significantly blunted the response to E2 treatment
(p < 0.001) a finding consistent with the reduction in
expression of ERα as a result of PGF2α treatment.
Discussion
A recent paper reported that women with variants of the
aromatase (CYP19A1) gene that are associated with a 10-
20% increase in circulating oestrogen levels after meno-
pause have an increased risk of endometrial cancer [42],
In the present study we have examined the patterns of
expression of ERα, the full length ERβ receptor (ERβ1)
and two ERβ splice variant isoforms (ERβ2, ERβ5) in well-
characterised stage I endometrioid adenocarcinomas. This
extends a preliminary study that discovered ERβ2 and
ERβ5 mRNAs were more abundant than those of ERβ4 in
human endometrium and Ishikawa cells [43].
In a fixed tissue set comprising 30 well characterised can-
cers (well, moderately and poorly differentiated) expres-
sion of ERα was reduced in the poorly differentiated
tissues a finding that is in agreement with previous reports
[14,44]. Although studies in rodents have demonstrated
that ERα-dependent gene activation plays a key role in
endometrial epithelial cell proliferation [45] in our sam-
ples proliferative activity of endometrial adenomas (as
Expression of mRNAs for ERα, ERβ1 (wild type) and two truncated ERβ variants (ERβ2 and ERβ5) in grade 1 endometrial can- cers Figure 1
Expression of mRNAs for ERα, ERβ1 (wild type) and two truncated ERβ variants (ERβ2 and ERβ5) in grade 1 
endometrial cancers. Samples n = 10 per group, concentrations were normalised against those of an internal control sam-
ple. A, ERα, note that the amount of mRNA was significantly lower (p < 0.0001) in samples graded as poor compared with 
those that were well or moderately differentiated; B, ERβ1 (full length wild-type); C, ERβ2 (ERβcx); D, ERβ5. There was no 
statistically significant difference between the levels of expression of ERβ variants between the different groups. Significant dif-
ferences between samples are indicated with letters a, b.BMC Cancer 2009, 9:330 http://www.biomedcentral.com/1471-2407/9/330
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Immunoexpression of ERs in endometrial cancers Figure 2
Immunoexpression of ERs in endometrial cancers. Tissues were classified as well (A-D), moderately (E-H) or poorly (J-
M) differentiated; main panels show closely adjacent sections from three cancer blocks to allow direct comparisons. All pro-
teins were immunolocalised to cell nuclei (see higher power inserts in panels e, f, c and d respectively). In the well and moder-
ately differentiated cancers expression was most intense in epithelial cell layers (arrowheads, panel A and inserts). Note that 
ERα was low/absent in poor grade cancers (J) but immunoexpression of ERβ1, 2, 5 was readily detected (K. L, M). Inserts in 
panels K, L, and M show negative controls for ERβ1, ERβ2 and ERβ5 antibodies respectively generated using primary antibodies 
pre-absorbed with specific peptides used for immunisation. Asterisks (*) label the stromal compartment that was well defined 
in the well differentiated cancers.BMC Cancer 2009, 9:330 http://www.biomedcentral.com/1471-2407/9/330
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Expression of PR paralleled that of ERα not ERβ Figure 3
Expression of PR paralleled that of ERα not ERβ. A. Expression of PR mRNA was significantly higher in cancers that 
were classified as well or moderately differentiated as compared with those with a poorly differentiated phenotype (p < 0.05, n 
= 10 cancers in each group, comparisons indicated by letters a, b). B. PR mRNA was significantly higher in Ishikawa A [ERα-
positive] compared to Ishikawa B [ERα-negative] after incubation with E2 for 16 (a) or 24 (b) hours (p < 0.01). Values are 
expressed as mean +/- SD of three independent experiments performed in duplicate. C. Fluorescent co-localisation as carried 
out using antibodies specific for ERα or ERβ1 (both green) and PR (red). The cancers illustrated were classified as well (code 
1614), moderately (code 1930) or poorly (c, codes 0001 and 1176) differentiated; at least 8 samples were analysed in each 
group. Co-expression was detected as yellow/orange immunofluoresence. In the well and moderately differentiated cancers 
expression of PR was most intense in epithelial cells and broadly overlapped with that of ERα (e.g. in cells indicated by arrows). 
Expression of PR was very low in the poorly differentiated cancers and appeared confined to cells with a fibroblast phenotype 
(**). Some ERβ1 positive cells were PR positive however most cells in the poorly differentiated cancers were ERβ1 positive 
and PR negative (green nuclei). Labels: L = lumen, S = stromal compartment, arrowheads = ERβ1 postive cells that are PR neg-
ative.BMC Cancer 2009, 9:330 http://www.biomedcentral.com/1471-2407/9/330
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determined by immunostaining for Ki67 or histone H3,
unpublished observations) was highest in the poorly dif-
ferentiated tumours even when they were ERα-negative
(not shown). These results agree with a recent study doc-
umenting increased expression of Ki67 and other cell
cycle regulators such as cyclin A during the progression
from a normal to malignant endometrial phenotype [46]
and higher expression of Ki67 in ERα-negative tumours
with a more aggressive phenotype [47].
To date studies on the role(s) played by ERβ in disease
progression, cell survival and proliferation have been
dominated by studies on breast cancer tissues and breast
cancer cell lines. In these samples over-expression of ERβ
results in anti-proliferative and pro-apoptotic effects [48]
and expression of ERβ2 correlates with favourable
response to endocrine therapy and improved survival
[49]. Other studies have reported no correlation between
expression of ERβ2 mRNA and response to tamoxifen
[50,51]. A recent study used tissue microarrays to deter-
mine expression of ERβ1, β2 and β5 in a series of 880
cases of primary invasive breast carcinomas from patients
with long term follow up. Expression of ERβ2 or ERβ5,
but not ERβ1 significantly correlated with overall survival
[39]. To date only two studies have examined expression
of ERβ in endometrial cancers. In both studies samples
were ERα-positive; one group reported detection of ERβ5
mRNA [16] the other reported finding no correlation
between ERβ mRNA expression and PR labeling index,
cell proliferation or histologic grade [15]. We believe this
is the first paper demonstrating immunoexpression of
ERβ5 protein in cell nuclei within stage 1 endometrial
adenocarcinomas regardless of whether they were well or
poorly differentiated. Expression of ERβ5 is not unique to
tumour cells and we have immunolocalised the protein to
multiple cell types in normal cycling endometrium, first
trimester decidua and placenta (Fitzgerald, MacPherson
and Saunders, unpublished observations). Molecular
Double immunohistochemistry for COX-2 (red) ERα (green) Figure 4
Double immunohistochemistry for COX-2 (red) ERα (green). Immunoexpression of COX-2 was confined to the 
cytoplasm; a greater proportion of the cells were immunopositive in the poorly differentiated tissue than in well or moderately 
differentiated samples. Immunoexpression of COX-2 and ERα appeared to be inversely related e.g. arrows COX-2pos/ERαneg 
cells.BMC Cancer 2009, 9:330 http://www.biomedcentral.com/1471-2407/9/330
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modelling of the ERβ5 protein suggests that it does not
contain a functional ligand-binding pocket [10]. ERβ5 has
been demonstrated to form a hetero-dimeric complex
with ERα which negatively regulated transcriptional activ-
ity [52]: this may explain why ERβ5 expression was asso-
ciated with a better prognosis in breast cancer [53]. Leung
et al [10] detected increased activation of an ERE-luci-
ferase reporter in HEK293 cells incubated with oestrogens
including E2 when cells were co-transfected with ERβ1
and ERβ5 compared with those transfected with ERβ1
alone.
In the current study expression of PR in endometrial ade-
nocarcinoma tissues broadly paralleled that of ERα with
minimal expression of PR in the poorly differentiated can-
cers even though these tissues maintained expression of
ERβ. In our ERαpos/ERβpos Ishikawa (A) cells expression of
PR mRNA and a luciferase gene driven by a consensus
3xERE promoter were both induced by E2 treatment. No
activity was detected in the ERαneg/ERβpos Ishikawa cells
(line B) even though they were able to activate the ERE-
luciferase when ERα was reintroduced into the cells sug-
gesting the lack of response was not due to lack of tran-
scriptional competence; both cell lines expressed similar
concentrations of ERβ5 mRNA. Our results are in agree-
ment with those of others [54] who reported that ERβ was
unable to up-regulate expression of the PRB promoter in
HeLa, BT-20 or Ishikawa cells although in SK-BR-3 cells
both receptors were able to repress promoter activity. The
potential that ERβ-dependent gene activation can occur in
the endometrial cancers is supported by the results of
studies using tamoxifen, a SERM that acts as a potent tran-
scriptional activator of ERβ at AP-1 response elements
[55]. Treatment with tamoxifen results in a more aggres-
sive endometrial cancer phenotype and development of a
distinctive 'tamoxifen-specific' gene profile [56,57].
Figure 5
Cell based studies suggest that local biosynthesis of prostag- landin could regulate expression of ERα and PR Figure 5
Cell based studies suggest that local biosynthesis of 
prostaglandin could regulate expression of ERα and 
PR. Incubation of Ishikawa cells with PGF2α resulted in 
reduced expression of ERα mRNA. Panel A, Samples which 
differed significantly from each other are indicated by letters 
a, b, c; p < 0.005 in all cases. Panel B, there was no significant 
impact on expression of ERβ1 mRNA between samples at 
the start or end of the experiment. Panel C, Samples which 
differed significantly from each other are indicated by letters 
a, b, c; p < 0.001 in all cases. Incubation of cells with E2 for 24 
h resulted in a significant increase in expression of PR mRNA 
this rise did not occur if cells were pre-incubated with 
PGF2α for 24 h. All values are expressed as mean +/- SD of 
three independent experiments performed in duplicate.BMC Cancer 2009, 9:330 http://www.biomedcentral.com/1471-2407/9/330
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Expression of COX-2 but not COX-1 is up-regulated in
endometrial adenocarcinoma compared with expression
levels observed in normal endometrium [27,28]. This is
associated with increased biosynthesis of prostaglandins
and increased expression of FP receptors resulting in a
stimulation of FP-receptor dependent signalling and pro-
duction of angiogenic factors. [29]. In addition there is
evidence that PGE2 can up-regulate expression of ster-
oidogenic genes including CYP19A1 and thereby contrib-
ute to increased local concentrations of oestrogenic
ligands that could bind ERα and/or ERβ [58]. We believe
the data in the present paper provide preliminary evi-
dence for a link between signalling via the FP receptor and
an apparent reduction in expression of ERα and PR. The
human ERα gene is transcribed from at least seven pro-
moters into multiple transcripts that vary in their 5' UTRs.
Tissue specific expression of transcripts has been docu-
mented as having differential use of promoters in normal
and cancerous breast tissue (reviewed in [59]). The signal-
ling pathway responsible for down regulation in the
amount of ERα mRNA after incubation of endometrial
Ishikawa cells with prostaglandin F2α requires further
investigation in order to determine whether the effects we
observed are mediated by transcriptional or post tran-
scriptional mechanism(s).
Conclusion
Our results shed new light on the interplay between PG
and ER-dependent patterns of gene expression in
endometrial cancers. First we would speculate that ligand-
dependent or ligand-independent activation of ERβ iso-
forms could have an impact on progression of endome-
trial cancers especially those with a more aggressive
phenotype that are ERα-negative and this merits further
investigation. Second, although increased biosynthesis of
prostaglandins is known to occur in endometrial cancers
we believe our study provides the first evidence that
down-regulation in expression of ERα, and the conse-
quent reduction in expression of PR, may be one of the
downstream consequences of F prostaglandin-dependent
signalling.
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